AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26997191 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting program
Number of subjects: 816
Study 25764255 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation consisting of 16 individual one-hour sessions of therapist-guided computer exercises.
Number of subjects: 92
Study 25764255 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention performed by the control group (CG).
Number of subjects: 92
Study 25764255 — intervention group
Group type: COMPARATOR
Intervention: Cognitive rehabilitation (SG) vs. Sham intervention (CG).
Number of subjects: 92
Study 23088514 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g/day of yellow passion fruit peel flour for two months
Number of subjects: 43
Study 21243915 — intervention group
Group type: EXPERIMENTAL
Intervention: 1xRDA MMS preparation (14 vitamins and minerals)
Number of subjects: 2100
Study 21243915 — intervention group
Group type: EXPERIMENTAL
Intervention: 2xRDA MMS preparation
Number of subjects: 2100
Study 21243915 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled effect of MMS preparations
Number of subjects: 2100
Study 21243915 — intervention group
Group type: EXPERIMENTAL
Intervention: 1xRDA MMS preparation
Number of subjects: 2100
Study 21243915 — intervention group
Group type: COMPARATOR
Intervention: Iron-folic acid supplementation
Number of subjects: 2100
Study 17379121 — intervention group
Group type: EXPERIMENTAL
Intervention: 3xED(95) bolus dose of cisatracurium at induction
Number of subjects: 30
Study 17379121 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of cisatracurium during the entire procedure
Number of subjects: 30
Study 15661841 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine 90 mM
Number of subjects: 6
Study 15661841 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanine-glucose 45:45 mM
Number of subjects: 6
Study 15661841 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-glucose 45:45 mM
Number of subjects: 6
Study 15661841 — intervention group
Group type: COMPARATOR
Intervention: Saline (sodium chloride 308 mmol/l)
Number of subjects: 6
Study 12039705 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse of insulin (0.03 U/kg s.c.) and dexamethasone (2 mg i.v.) with transient hyperglycemia
Number of subjects: 29
Study 12039705 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (0.03 U/kg and 0.06 U/kg) with dexamethasone without transient hyperglycemia
Number of subjects: 29
Study 12039705 — intervention group
Group type: COMPARATOR
Intervention: Fasting with or without dexamethasone
Number of subjects: 29
Study 12039705 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse of insulin and glucose without dexamethasone
Number of subjects: 29
Study 10534548 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid injection (25 mg/ml prednisolone acetate)
Number of subjects: 106
Study 10534548 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthetic control
Number of subjects: 106
Study 7597072 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine added to zidovudine for 8 weeks
Number of subjects: 16
Study 7597072 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine alone
Number of subjects: 16
Study 1971118 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg alprazolam
Number of subjects: 14
Study 1971118 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.37 mg alprazolam
Number of subjects: 14
Study 1971118 — intervention group
Group type: COMPARATOR
Intervention: 5 mg diazepam
Number of subjects: 14
Study 394279 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (50 mg, rising to 150 mg per day)
Number of subjects: 13
Study 394279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30805363 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk-fill composite only
Number of subjects: 80
Study 30805363 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk-fill/Ribbond
Number of subjects: 80
Study 30805363 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk-fill/additional Ribbond
Number of subjects: 80
Study 30805363 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermomechanical aging after restorations (BF-TMA, PRF1-TMA, PRF2-TMA)
Number of subjects: 80
Study 30805363 — intervention group
Group type: COMPARATOR
Intervention: Control groups (Group IN and Group IN-TMA)
Number of subjects: 80
Study 28077587 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP-CTX arm
Number of subjects: 500
Study 28077587 — intervention group
Group type: COMPARATOR
Intervention: CTX arm
Number of subjects: 500
Study 26053030 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir (HIV-1 protease inhibitor)
Number of subjects: 215
Study 26053030 — intervention group
Group type: COMPARATOR
Intervention: NNRTI-based regimens
Number of subjects: 215
Study 24653917 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory short-term training with novel stimuli (/su/ and /∫u/) for about 20 minutes.
Number of subjects: 20
Study 24653917 — intervention group
Group type: COMPARATOR
Intervention: Non-training group (control).
Number of subjects: 20
Study 22193796 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotics with high risk of causing metabolic abnormalities
Number of subjects: 1898
Study 22193796 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotics with medium risk of causing metabolic abnormalities
Number of subjects: 1898
Study 22193796 — intervention group
Group type: COMPARATOR
Intervention: Preexisting metabolic conditions (diabetes, hyperlipidemia, hypertension)
Number of subjects: 1898
Study 19675533 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan challenge
Number of subjects: 30
Study 19675533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17351694 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (twice weekly)
Number of subjects: 125
Study 17351694 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercises (5 times a week)
Number of subjects: 125
Study 15491274 — intervention group
Group type: EXPERIMENTAL
Intervention: Women showing cognitive balance among in-group bias, identity, and self-esteem.
Number of subjects: 0
Study 15491274 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-female bias observed in participants favoring their mothers over fathers.
Number of subjects: 0
Study 15491274 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexually experienced men with positive attitudes toward sex.
Number of subjects: 0
Study 11561239 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapeziectomy alone
Number of subjects: 67
Study 11561239 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapeziectomy with tendon interposition
Number of subjects: 67
Study 11561239 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapeziectomy with ligament reconstruction
Number of subjects: 67
Study 11561239 — intervention group
Group type: COMPARATOR
Intervention: K-wire placement across the trapezial void
Number of subjects: 67
Study 9029748 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine (50 mg for 1 day and 100 mg for 6 days)
Number of subjects: 12
Study 9029748 — intervention group
Group type: EXPERIMENTAL
Intervention: Griseofulvin (500 mg for 9 days)
Number of subjects: 12
Study 7935655 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (400 mg/kg)
Number of subjects: 255
Study 7935655 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.1% albumin)
Number of subjects: 255
Study 3364221 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation interventions (specific interventions not detailed)
Number of subjects: 333
Study 3364221 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy beliefs
Number of subjects: 333
Study 30461315 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT‐I)
Number of subjects: 51
Study 30461315 — intervention group
Group type: COMPARATOR
Intervention: Attention Control
Number of subjects: 51
Study 30423449 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut OIT with a maintenance dose of 125 to 250 mg peanut protein
Number of subjects: 62
Study 30423449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 30423449 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut OIT
Number of subjects: 62
Study 28388246 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylic acid peeling combined with vitamin C mesotherapy
Number of subjects: 50
Study 28388246 — intervention group
Group type: COMPARATOR
Intervention: Salicylic acid peeling alone
Number of subjects: 50
Study 25825393 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 40
Study 25825393 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA)
Number of subjects: 40
Study 25825393 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 40
Study 23649189 — intervention group
Group type: EXPERIMENTAL
Intervention: ixabepilone 16 mg/m(2) weekly plus bevacizumab 10 mg/kg Q2W (Arm A: n = 46)
Number of subjects: 123
Study 23649189 — intervention group
Group type: EXPERIMENTAL
Intervention: ixabepilone 40 mg/m(2) Q3W plus bevacizumab 15 mg/kg Q3W (Arm B: n = 45)
Number of subjects: 123
Study 23649189 — intervention group
Group type: COMPARATOR
Intervention: paclitaxel 90 mg/m(2) weekly plus bevacizumab 10 mg/kg Q2W (Arm C: n = 32)
Number of subjects: 123
Study 21411446 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib plus simvastatin (GS) 250 mg/d and 40 mg/d respectively
Number of subjects: 106
Study 21411446 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib alone (G) 250 mg/d
Number of subjects: 106
Study 21411446 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib plus simvastatin (GS)
Number of subjects: 106
Study 21411446 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib alone (G)
Number of subjects: 106
Study 21411446 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib plus simvastatin (GS) in patients with wild-type EGFR nonadenocarcinomas
Number of subjects: 106
Study 21411446 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib alone (G) in patients with wild-type EGFR nonadenocarcinomas
Number of subjects: 106
Study 19289454 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine plus lithium or divalproex
Number of subjects: 628
Study 19289454 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus lithium or divalproex
Number of subjects: 628
Study 19289454 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 628
Study 19289454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 628
Study 17894261 — intervention group
Group type: EXPERIMENTAL
Intervention: Social-contextual intervention targeting fruit, vegetable, and red meat consumption, multivitamin use, and physical activity.
Number of subjects: 456
Study 14981107 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A: subcutaneous interferon alfa‐2a (sc‐IFN‐alpha‐2a), subcutaneous interleukin‐2 (sc‐IL‐2), and intravenous (IV) fluorouracil
Number of subjects: 341
Study 14981107 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B: Arm A treatment combined with per oral 13‐cis‐retinoic acid
Number of subjects: 341
Study 14981107 — intervention group
Group type: COMPARATOR
Intervention: Arm C: subcutaneous interferon alfa‐2a (sc‐IFN‐alpha‐2a) and IV vinblastine
Number of subjects: 341
Study 11577945 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg/day
Number of subjects: 66
Study 11577945 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg/day
Number of subjects: 66
Study 11577945 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg/day plus Azithromycin 500 mg/day
Number of subjects: 66
Study 9685820 — intervention group
Group type: EXPERIMENTAL
Intervention: iodixanol 320 mg I/ml
Number of subjects: 30
Study 9685820 — intervention group
Group type: EXPERIMENTAL
Intervention: iomeprol 300 mg I/ml
Number of subjects: 30
Study 9685820 — intervention group
Group type: EXPERIMENTAL
Intervention: ioxaglate 320 mg I/ml
Number of subjects: 30
Study 8015643 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (2-3 mg/kg/day) twice a week for 12 months
Number of subjects: 61
Study 8015643 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 61
Study 2603453 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 900 mg q8h admixed with gentamicin 1.5 mg/kg
Number of subjects: 0
Study 2603453 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin 600 mg q6h with gentamicin 1.5 mg/kg given separately
Number of subjects: 0
Study 811982 — intervention group
Group type: EXPERIMENTAL
Intervention: Prindolol (2 x 5 mg daily)
Number of subjects: 61
Study 811982 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of prindolol (2 x 5 mg) + clopamide (10 mg)
Number of subjects: 61
Study 811982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 29166636 — intervention group
Group type: EXPERIMENTAL
Intervention: RegentK
Number of subjects: 20
Study 29166636 — intervention group
Group type: COMPARATOR
Intervention: MMT (myofascial mobilization technique)
Number of subjects: 20
Study 28807045 — intervention group
Group type: EXPERIMENTAL
Intervention: Best medical treatment plus renal artery stenting (stent group)
Number of subjects: 86
Study 28807045 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment (BMT group)
Number of subjects: 86
Study 25924670 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential Learning (EL)
Number of subjects: 184
Study 25924670 — intervention group
Group type: COMPARATOR
Intervention: Traditional Lecturing (TL)
Number of subjects: 184
Study 22589424 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily light smokers (3‐9 cigarettes/day)
Number of subjects: 131
Study 22589424 — intervention group
Group type: COMPARATOR
Intervention: Heavier smokers (≥ 10 cigarettes/day)
Number of subjects: 131
Study 21523384 — intervention group
Group type: EXPERIMENTAL
Intervention: Oily vitamin D(3) preparation
Number of subjects: 42
Study 21523384 — intervention group
Group type: COMPARATOR
Intervention: Alcoholic vitamin D(3) preparation
Number of subjects: 42
Study 18461262 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic neck pain (non-traumatic, non-specific)
Number of subjects: 45
Study 18461262 — intervention group
Group type: EXPERIMENTAL
Intervention: Whiplash-associated disorders
Number of subjects: 45
Study 18461262 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control)
Number of subjects: 45
Study 18461262 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic neck pain and whiplash-associated disorders
Number of subjects: 45
Study 16922663 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose microencapsulated vitamin D(3) 100 000 IU orally at baseline, then 3 monthly (three or more doses)
Number of subjects: 137
Study 16922663 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated subjects observed contemporaneously)
Number of subjects: 137
Study 14500058 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (decreased caloric intake and increased physical activity)
Number of subjects: 5000
Study 14500058 — intervention group
Group type: COMPARATOR
Intervention: Control condition (diabetes support and education)
Number of subjects: 5000
Study 14500058 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 5000
Study 14500058 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 5000
Study 9841303 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg daily)
Number of subjects: 9014
Study 9841303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9014
Study 7626373 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypokinetic, hyperhydrated subjects (HHS) with phosphate, fluid, and salt supplementation
Number of subjects: 30
Study 7626373 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypokinetic subjects (HS) without supplementation
Number of subjects: 30
Study 7626373 — intervention group
Group type: COMPARATOR
Intervention: Control group (exercise at 14.4 km/d)
Number of subjects: 30
Study 2792664 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (0.2, 1.0, or 5.0 mg/kg.h)
Number of subjects: 10
Study 2792664 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (1 or 5 mg/kg.h) with an 800-kcal meal
Number of subjects: 10
Study 2792664 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (5 mg/kg.h) without caerulein or the test meal
Number of subjects: 10
Study 2792664 — intervention group
Group type: COMPARATOR
Intervention: Caerulein (7.5 to 120 ng/kg.h) without loxiglumide
Number of subjects: 10
Study 2792664 — intervention group
Group type: COMPARATOR
Intervention: 800-kcal meal without loxiglumide
Number of subjects: 10
Study 653653 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 gauge needle
Number of subjects: 99
Study 653653 — intervention group
Group type: COMPARATOR
Intervention: 22 gauge needle
Number of subjects: 99
Study 30535357 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-factor measurement model composed of negative affect, somatic symptoms, sleep problems, positive affect, and craving
Number of subjects: 1246
Study 30535357 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-factor measurement model
Number of subjects: 1246
Study 30896608 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU/day of vitamin D3
Number of subjects: 50
Study 30896608 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU/day of vitamin D3
Number of subjects: 50
Study 27983887 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularisation approach
Number of subjects: 3
Study 27983887 — intervention group
Group type: COMPARATOR
Intervention: PPCI of the culprit artery alone
Number of subjects: 3
Study 24944260 — intervention group
Group type: EXPERIMENTAL
Intervention: Droxidopa (100-600 mg 3 times daily)
Number of subjects: 162
Study 22517315 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine (25 mg)
Number of subjects: 16
Study 22517315 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (0.4 mg)
Number of subjects: 16
Study 22517315 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (1 mg)
Number of subjects: 16
Study 22517315 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclizine (25 mg)
Number of subjects: 16
Study 22517315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 19913154 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical block
Number of subjects: 72
Study 19913154 — intervention group
Group type: COMPARATOR
Intervention: No local anesthesia (Control)
Number of subjects: 72
Study 17313946 — intervention group
Group type: EXPERIMENTAL
Intervention: IV human albumin
Number of subjects: 0
Study 17313946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15379738 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone administered with 30 min delay
Number of subjects: 28
Study 15379738 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administered entacapone
Number of subjects: 28
Study 15379738 — intervention group
Group type: COMPARATOR
Intervention: Carbidopa/L-dopa
Number of subjects: 28
Study 11419239 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.15 mg.kg‐1 for induction, 0.12 mg.kg‐1.h‐1 for continuous infusion)
Number of subjects: 40
Study 9814642 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-reduced blood transfusions
Number of subjects: 0
Study 9814642 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic blood transfusion
Number of subjects: 0
Study 7954541 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 0
Study 7954541 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose combinations of different diuretics (e.g., loop diuretics with thiazides)
Number of subjects: 0
Study 2570959 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum with high antibody titre against human rotavirus
Number of subjects: 120
Study 2570959 — intervention group
Group type: COMPARATOR
Intervention: Artificial infant formula (control)
Number of subjects: 120
Study 381628 — intervention group
Group type: EXPERIMENTAL
Intervention: Alexidine mouthwash
Number of subjects: 42
Study 381628 — intervention group
Group type: COMPARATOR
Intervention: Placebo oral rinse
Number of subjects: 42
Study 31488202 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse probability weighting with complete measurement of time-varying covariates
Number of subjects: 0
Study 31488202 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse probability weighting with yearly measurement intervals
Number of subjects: 0
Study 31488202 — intervention group
Group type: COMPARATOR
Intervention: Naive estimator ignoring time-varying confounding
Number of subjects: 0
Study 29493523 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish massage combined with acupressure
Number of subjects: 40
Study 29493523 — intervention group
Group type: COMPARATOR
Intervention: Swedish massage only
Number of subjects: 40
Study 26011141 — intervention group
Group type: EXPERIMENTAL
Intervention: FPHT sodium injection (400 mg PHT acid equivalent)
Number of subjects: 10
Study 26011141 — intervention group
Group type: EXPERIMENTAL
Intervention: FPHT sodium injection
Number of subjects: 10
Study 26011141 — intervention group
Group type: COMPARATOR
Intervention: PHT sodium injection (400 mg PHT acid equivalent)
Number of subjects: 10
Study 23771848 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine group (n=35)
Number of subjects: 65
Study 23771848 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 65
Study 21812262 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaohe Ganpi Recipe (TGR)
Number of subjects: 27
Study 21812262 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment of HSCT (Control)
Number of subjects: 27
Study 20024753 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly Administered Antiretroviral Therapy (DAART)
Number of subjects: 127
Study 20024753 — intervention group
Group type: COMPARATOR
Intervention: Self-Administered Therapy
Number of subjects: 127
Study 17058023 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) intervention for weight loss through exercise and diet modification, once weekly for 16 weeks.
Number of subjects: 85
Study 17058023 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 85